JP2020512350A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512350A5
JP2020512350A5 JP2019553055A JP2019553055A JP2020512350A5 JP 2020512350 A5 JP2020512350 A5 JP 2020512350A5 JP 2019553055 A JP2019553055 A JP 2019553055A JP 2019553055 A JP2019553055 A JP 2019553055A JP 2020512350 A5 JP2020512350 A5 JP 2020512350A5
Authority
JP
Japan
Prior art keywords
indazole
carboxamide
phenyl
composition according
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512350A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/024603 external-priority patent/WO2018183354A1/en
Publication of JP2020512350A publication Critical patent/JP2020512350A/ja
Publication of JP2020512350A5 publication Critical patent/JP2020512350A5/ja
Pending legal-status Critical Current

Links

JP2019553055A 2017-03-27 2018-03-27 ニラパリブ組成物 Pending JP2020512350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Publications (2)

Publication Number Publication Date
JP2020512350A JP2020512350A (ja) 2020-04-23
JP2020512350A5 true JP2020512350A5 (cg-RX-API-DMAC10.html) 2021-05-06

Family

ID=63676949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553055A Pending JP2020512350A (ja) 2017-03-27 2018-03-27 ニラパリブ組成物

Country Status (14)

Country Link
US (3) US11091459B2 (cg-RX-API-DMAC10.html)
EP (1) EP3600314A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020512350A (cg-RX-API-DMAC10.html)
KR (1) KR20200014736A (cg-RX-API-DMAC10.html)
CN (1) CN110944638A (cg-RX-API-DMAC10.html)
AU (2) AU2018246214B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019020211A2 (cg-RX-API-DMAC10.html)
CA (1) CA3058375C (cg-RX-API-DMAC10.html)
EA (1) EA201992177A1 (cg-RX-API-DMAC10.html)
IL (1) IL269630A (cg-RX-API-DMAC10.html)
MX (1) MX2019011496A (cg-RX-API-DMAC10.html)
SG (1) SG11201909011PA (cg-RX-API-DMAC10.html)
TW (1) TWI761476B (cg-RX-API-DMAC10.html)
WO (1) WO2018183354A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
JP2023524794A (ja) 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
JP2026517228A (ja) 2023-05-17 2026-05-28 テサロ, インコーポレイテッド がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
MX2010004028A (es) * 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
EP2240466B1 (en) * 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク. 多環系化合物の新規形態
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
EP3424909A1 (en) 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
HRP20240136T1 (hr) * 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) * 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Similar Documents

Publication Publication Date Title
ES2380297T3 (es) Hidrocloruro de nalmefeno dihidrato
Mulye et al. Improvement in physicochemical properties of ezetimibe using a crystal engineering technique
CN102639531B (zh) 噻托溴铵的无水合物
CN104797566A (zh) 沃替西汀氢溴酸盐的新结晶形式
JP2022502500A5 (cg-RX-API-DMAC10.html)
JP5184511B2 (ja) 新しい結晶形態のラミブジン
CN103965116B (zh) 半5-氟胞嘧啶盐、其制备方法及应用
CN1970547B (zh) 非布司他的晶型及其制备方法
PT2773620T (pt) Cloridrato de ivabradina de forma iv
JP2009534373A5 (cg-RX-API-DMAC10.html)
RU2607515C2 (ru) Кристаллическая форма натриевой соли 4-трет-бутил-n-{ 4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил} -бензолсульфонамид
KR20200030106A (ko) 빌란테롤 트리페나테이트의 신규의 결정형 및 이들의 제조방법
CN103819379A (zh) 维生素d3的胆甾烷醇共结晶及其制备方法和应用
WO2006057397A1 (ja) (s)-(-)-1-(4-フルオロイソキノリン-5-イル)スルホニル-2-メチル-1,4-ホモピペラジン塩酸塩・二水和物
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
BR112014001530B1 (pt) Formas polimórficas do sal de sódio de 4-terc-butiln-[4-cloro-2-(1-óxi-piridina-4-carbonil)- fenil]-benzeno sulfonamida, composição farmacêutica e método de produção da mesma
CA2767992A1 (en) 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
PT2838892T (pt) Forma sólida isolada de monocloridrato de anamorelina com baixa razão molar cloreto:anamolerina e baixo teor de solvente orgânico residual
JP2010540440A5 (cg-RX-API-DMAC10.html)
CN102351784B (zh) 一种盐酸贝尼地平晶型及其应用
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
TW201917117A (zh) 一種炔基吡啶類脯胺醯羥化酶抑制劑的晶型及其製備方法
CN102093309B (zh) 非布司他的晶型及其制备方法
CN115536654A (zh) 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用
JP5265876B2 (ja) アンドラストの新規で安定な結晶構造体